Guidance, NICE advice and quality standards in development | Guidance

Showing 261 to 270 of 300

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]	Technology appraisal guidance	15 October 2025
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]	Technology appraisal guidance	17 December 2025
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]	Technology appraisal guidance	20 August 2025
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401	Technology appraisal guidance	TBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance	28 July 2027
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]	Technology appraisal guidance	26 November 2025
Teprotumumab for treating thyroid eye disease [ID6432]	Technology appraisal guidance	13 August 2025
Third molars (impacted) - prophylactic removal [ID898]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]	Technology appraisal guidance	TBC